van der Kaaden M E, Rijken D C, Groeneveld E, van Berkel T J, Kuiper J
Division of Biopharmaceutics, Sylvius Laboratory, Leiden/Amsterdam Center for Drug Research, University of Leiden, The Netherlands.
Thromb Haemost. 1995 Aug;74(2):722-9.
The recognition systems mediating the clearance of glycosylated high molecular weight single-chain urokinase-type plasminogen activator (HMW-scu-PA, produced in human embryonic kidney cells) and recombinant non-glycosylated scu-PA (rscu-PA, produced in E. coli) were analyzed by studying their binding characteristics to freshly isolated rat parenchymal liver cells. The binding of 125I-HMW-scu-PA at 4 degrees C was calcium-dependent and of high affinity (Kd = 37.6 nM) and could be inhibited by low molecular weight two-chain u-PA (LMW-tcu-PA) and lactose, but not by the low density lipoprotein receptor-related protein (LRP)-associated 39-kDa protein (RAP), rscu-PA or a mutant form lacking amino acids 11-135 (Delta 125-rscu-PA). Removal of the carbohydrate side chain of HMW-scu-PA by treatment with N-glycosidase F, completely reduced the specific binding to the parenchymal cells and strongly reduced its competition with 125I-HMW-scu-PA in cell binding. Recombinant scu-PA also bound with high affinity (Kd = 38.7 nM) to the parenchymal liver cells. The binding of 125I-rscu-PA could be competed for by unlabeled rscu-PA while Delta 125-rscu-PA, LMW-tcu-PA or lactose were ineffective. In contrast to HMW-scu-PA, binding of 125I-rscu-PA could be effectively inhibited by RAP (Ki = 1.1 nM), while also its association and degradation, as determined at 37 degrees C, were inhibited by RAP. Pretreatment of the parenchymal cells with proteinase K supplied further evidence for the involvement of two different receptor systems.(ABSTRACT TRUNCATED AT 250 WORDS)
通过研究糖基化高分子量单链尿激酶型纤溶酶原激活剂(HMW - scu - PA,在人胚肾细胞中产生)和重组非糖基化scu - PA(rscu - PA,在大肠杆菌中产生)与新鲜分离的大鼠肝实质细胞的结合特性,分析了介导其清除的识别系统。4℃下125I - HMW - scu - PA的结合是钙依赖性的且具有高亲和力(Kd = 37.6 nM),可被低分子量双链u - PA(LMW - tcu - PA)和乳糖抑制,但不能被低密度脂蛋白受体相关蛋白(LRP)相关的39 kDa蛋白(RAP)、rscu - PA或缺乏氨基酸11 - 135的突变形式(Δ125 - rscu - PA)抑制。用N - 糖苷酶F处理去除HMW - scu - PA的碳水化合物侧链,完全降低了与实质细胞的特异性结合,并强烈降低了其在细胞结合中与125I - HMW - scu - PA的竞争能力。重组scu - PA也以高亲和力(Kd = 38.7 nM)与肝实质细胞结合。125I - rscu - PA 的结合可被未标记的rscu - PA竞争,而Δ125 - rscu - PA、LMW - tcu - PA或乳糖则无效。与HMW - scu - PA不同,125I - rscu - PA的结合可被RAP有效抑制(Ki = 1.1 nM),同时其在37℃下的结合和降解也被RAP抑制。用蛋白酶K预处理实质细胞为两种不同受体系统的参与提供了进一步证据。(摘要截短于250字)